<DOC>
	<DOCNO>NCT02698124</DOCNO>
	<brief_summary>Prospective multicenter , open-lab el , observational , single arm study decitabine . Subjects elderly patient newly diagnose , treatment-naïve AML unfit receive candidate intensive induction chemotherapy ( iIC )</brief_summary>
	<brief_title>Decitabine Chemotherapy Unfit Korean AML Patients Real Practice</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Newly diagnose therapynaïve AML ( bone marrow peripheral blood blast count ≥20 % ) 2 . 65 year age old 3 . Taking informed consent signature date 4 . Not eligible iIC base either : ) ≥75 year age ii ) comorbidity iii ) secondary AML iv ) poor performance ( ECOG ≥2 ) v ) Poorrisk NCCN Guideline version 1.2015 vi ) subject 's choice ( refusal iIC ) investigator 's judgement incompatible iIC 1 . Candidate iIC time enrollment 2 . Promyelocytic leukemia , AML ( 15 ; 17 ) PML/RARα rearrangement 3 . AML ( 9 ; 22 ) BCR/ABL rearrangement 4 . Leukemia central nervous system involvement 5 . Extramedullary myeloid sarcoma without bone marrow involvement 6 . Prior treatment decitabine azacitidine cause 7 . Any leukemiaspecific therapy , except hydroxyurea reduce leukemic cell prior decitabine 8 . Second malignancy currently require active therapy except breast prostate cancer stable respond endocrine therapy , curatively resect nonmelanoma skin cancer intraepithelial cancer 9 . Premenopausal woman 10 . Severe active infection 11 . Uncontrolled bleed Hypersensitivity decitabine</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>